Clinical Trial: Ameparomo Capsules 250 mg Drug Use Investigation
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Observational
Official Title: Drug Use Investigation Of Paromomycin. (Regulatory Post Marketing Commitment Plan).
Brief Summary: This Study is intended to evaluate the safety and effectiveness of Ameparomo Capsules 250 mg under actual medical practice.
Detailed Summary:
Sponsor: Pfizer
Current Primary Outcome: Number of Paticipants With Adverse Events (AEs) by Seriousness and Relationship to Treatment [ Time Frame: Maximum 10 days ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Number of Participants With Clinical Response of Cure [ Time Frame: Maximum 3 months ]
Original Secondary Outcome: Same as current
Information By: Pfizer
Dates:
Date Received: February 9, 2016
Date Started: October 2015
Date Completion: September 2019
Last Updated: May 2, 2017
Last Verified: May 2017